BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Korea's Coreline Soft partners with Optellum to advance AI across lung cancer pathway

August 14, 2026 | News

To make Coreline Soft's FDA-cleared lung nodule detection capability available through Optellum's LungOSÂ® platform



UK-based Optellum and South Korea's Coreline Soft have announced their intent to collaborate across geographies and multiple disease areas to advance artificial intelligence (AI)-enabled lung cancer care across the lung nodule pathway.

Under the proposed collaboration, Optellum would make Coreline Soft's FDA-cleared computer-aided detection (CADe) software for lung nodules, AVIEW Lung Nodule CAD, available through LungOS®, Optellum's end-to-end AI-powered platform for thoracic care.

The proposed collaboration is intended to connect Coreline Soft's FDA-cleared image-based CADe capability with Optellum's CADx, risk assessment, and care management workflow, supporting a more integrated pathway from detection to prioritisation and follow-up.

Lung cancer remains one of the world's most urgent healthcare challenges, with outcomes strongly linked to how early the disease is diagnosed and treated. Through this collaboration, Optellum and Coreline Soft aim to support clinicians and health systems with a more connected approach to finding, prioritizsng, and managing these lung nodule patients, helping enable earlier assessment and timely intervention.

Coreline Soft's AVIEW Lung Nodule CAD is FDA-cleared CADe software designed to assist radiologists in detecting lung nodules during review of chest CT examinations. The software supports radiologists in the review of chest CT images.

The LungOS® platform for opportunistic screening of incidental lung nodules includes Optellum Virtual Nodule Clinic® with Patient Discovery AI and reimbursed Lung Cancer Prediction AI, supporting clinicians in identifying, risk-stratifying, and managing patients with lung nodules. Optellum VNC is cleared in the US and Australia for incidental lung nodules, as well as for screening-detected and incidental lung nodules in the EU, UK, and Switzerland.